Cytomegalovirus (CMV) remains an important pathogen among recipients of solid organ and hematopoietic progenitor cell allotransplantation. 1,2 Although debate persists on the merits and drawbacks of preemptive vs prophylactic approaches to CMV disease prevention in this context, 3,4 some means of virus detection in peripheral blood has become standard procedure in most clinical laboratories. Techniques such as shell vial propagation, immunologic detection of circulating leukocytes containing CMV lower matrix protein pp65 (ie, antigenemia), and mRNA or DNA amplification methods have all been proposed for such purposes. [5] [6] [7] [8] Disadvantages to each method exist, however, including poor sensitivity on the part of culture-based assays 5 and lack of standardization for nucleic acid amplification techniques. 9,10 With respect to CMV antigenemia testing, a major limitation is the complexity of the process and, as a result, the considerable hands-on technologist time required for its performance.
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In support of an active hematopoietic cell transplant program, the clinical virology laboratory at M. D. Anderson Cancer Center, Houston, TX, performs approximately 15,000 CMV antigenemia assays annually. For high-volume laboratories such as ours, a minor procedural curtailment could potentially effect a sizable reduction in overall laboratory resource expenditure. In an effort to streamline our test procedure, therefore, we compared an abbreviated direct whole blood (WB) lysis protocol with our current peripheral blood leukocyte (PBL)-enriched blood fraction protocol for quantitative CMV antigenemia testing.
Materials and Methods
From November 2006 to January 2007, 367 patient samples were randomly selected from the routine CMV antigenemia morning runs and prospectively analyzed by each of 2 methods as described subsequently. After this, an additional 40 samples obtained from leukopenic patients were selected and studied using a modification of the WB method.
PBL Method
Leukocyte-rich fractions were extracted from 8 mL of acid citrate dextrose-anticoagulated whole blood using 2 mL of a dextran separation solution (Light Diagnostics, Chemicon International, Temecula, CA) by sedimentation for 25 minutes. WBC-rich supernatants were then removed and centrifuged (250g for 5 minutes at 6°C). For erythrocyte hemolysis, pellets were resuspended in 5 mL of 0.9% ammonium chloride and incubated for 5 minutes at 4°C. Resultant leukocytes were then cleared of residual erythrocyte material by 2 serial centrifugation-wash steps in cold phosphate buffered saline (PBS). Finally, WBCs were resuspended in PBS to a standardized turbidity of approximately 2.0 McFarland. Two slides were prepared for each sample by cytocentrifugation (Cyto-Tek Centrifuge, Sakura Finetek USA, Torrance, CA) using 150 µL of the WBC suspension per slide. The slides were fixed in formalin and stained with a commercially available kit (CMV pp65 Antigenemia IFA; Chemicon International), according to manufacturer's instructions. For positive samples, quantitative results of pp65+ cells per 10 6 WBCs were calculated following manual (hemocytometer) cell count of the final WBC suspension.
WB Method
Leukocytes were obtained by directly hemolyzing 200 µL of whole blood using 5 mL of 0.9% ammonium chloride for 5 minutes at 4°C. The WBCs were then washed twice in cold PBS to eliminate remaining erythrocyte debris and resuspended in a volume of 300 µL of PBS. The entire final suspension was divided between 2 cytocentrifuge slides. Slides were fixed with formalin and stained with a second commercially available kit (CMV pp65 Antigenemia IFA, CINA kit, Argene, Varilhes, France) according to the manufacturer's instruction. For antigenemic samples, quantitative results of pp65+ cells per 10 6 WBCs were calculated using the total WBC count from the concomitant CBC (performed on an automated analyzer in hematology).
A second phase of the study focusing solely on leukopenic samples was conducted, which utilized a procedural modification that consisted of an adjustment in the whole blood aliquot volume for direct hemolysis from 200 to 500 µL. All other protocol details were as outlined above.
Definitions and Statistics
For sensitivity, specificity, and predictive value data, true-positive values were defined as results positive by both methods or results positive by just one method that were corroborated by a subsequent or previous positive antigenemia result for a given patient obtained within 2 weeks of the experimental result. Agreement between quantitative values was assessed by using the Wilcoxon signed rank test and by the method of Bland and Altman. 11 When applicable, the Fisher exact test for comparison of proportions and the unpaired t test for comparison of means were used. Two-tailed P values were considered significant when they were .05 or less.
Results
Immunofluorescence patterns and intensity were generally satisfactory using both protocols. Whereas the PBL method seemed to stain pp65+ cells more sharply than did the WB method, background cells (and, hence, focal plane) were more readily discernible using the latter, resulting in a somewhat easier screening process.
Qualitative Antigenemia
Of 367 patient samples tested, 4 were excluded owing to insufficient cells for analysis by the PBL method, although each was negative by the WB method. An additional 4 samples had no orders for CBC, which precluded pp65+ cell quantitation using the WB protocol. Each of the 4 was negative by both methods, however, and were all included in the analysis. A total of 51 (14.0%) of 363 samples were positive by one or both methods zTable 1z. Based on a review of prior and subsequent antigenemia results for individual patients, 2 of the 51 positive values were determined to be false-positives. Both were identified by the WB method and contained only 1 pp65+ cell/10 6 WBCs. Sensitivity, specificity, negative predictive value, and positive predictive value calculations were comparable between the 2 methods (Table 1) . 99; unpaired t test). Stratification of qualitative results by WBC count zTable 2z confirmed that detection rates were comparable between methods for specimens having WBC levels of more than 3,000/µL (3.0 × 10 9 /L), with 67% (28/42) and 79% (33/42) of true-positive samples detected by the PBL and WB methods, respectively (P = .33; Fisher exact test). Among the 78 remaining leukopenic samples, 7 of 7 true-positives were detected by the PBL method, whereas 4 of 7 were identified by the WB method. The low total number of pp65+ leukopenic samples precluded statistical inference.
Leukocyte Counts
After the initial study, we extended our observations to include 40 additional leukopenic samples and adjusted the WB protocol to incorporate a slightly larger whole blood volume (500 µL). Two samples with insufficient cells for analysis by the WB method were excluded. Of the remaining 38, 6 true-positive results were identified by one or both methods zTable 3z. In addition, a single false-positive result (again having 1 pp65+ cell/10 6 WBCs) by the WB method was observed. The PBL and WB methods detected 4 of 6 and 5 of 6 true positives, respectively (Table 3) .
Quantitative Antigenemia
For the 23 concordantly positive samples, Wilcoxon signed rank testing demonstrated no statistical difference in quantitative values (P = .80). Similarly, correlation was high (r = 0.99), although the scatter plot depicted larger discrepancies among samples with higher levels of antigenemia zFigure 1z. As a result, all data were log-transformed and the degree of clinical agreement was estimated. 11 Assessment of the relationship between differences in quantitative values and their respective means zFigure 2z demonstrated that for 95% of samples, results by the WB method could be expected to vary between 0.1 (antilog -0.912) and 10 (antilog 1.020) times that of the reference (PBL) method. By comparison, a similar calculation to define precision of the PBL method using split samples demonstrated intra-assay variability ranging from 0.6 (antilog -0.197) to 4 (antilog 0.592) with 95% confidence 
Resource Utilization
To evaluate overall technical time required by the 2 protocols, we randomly selected 7 days from the initial study period for comparison of time to assay completion. This was crudely measured as the duration between initiation of a run and issuance of all results. A total of 128 samples were tested during the morning run on these days (8-32/day). The total time required for testing was 54.25 hours (6.0-8.75 h/d) for the PBL method and 41.75 hours (3.5-7.0 h/d) for the WB method. The calculated overall savings of approximately 1 hour /10 tests (or 1-3 h/d based on 128 total samples) is a sizable underestimate, however, given the fact that from 1 to 3 technologists contribute to the execution of our PBL protocol on any given day.
Discussion
In an effort to increase the efficiency of CMV antigenemia testing in our laboratory, we evaluated a modified procedure that entails direct lysis of 200-to 500-µL aliquots of whole blood. This technique not only eliminates the dextran leukocyte separation step but also precludes the need for manual hemocytometer counts by permitting interrogation of the entire leukocyte population of a whole blood aliquot. As expected, we measured a substantial reduction in resource expenditure (minimum average of 1 h/10 tests performed) using the modified procedure. However, projected savings might be considerably higher for laboratories that routinely adjust WBC concentrations for all samples before cytocentrifugation and staining steps. Our standard PBL procedure, by contrast, uses a turbidity reference for estimation of leukocyte concentration, making manual WBC quantitation necessary only when samples are identified as positive.
Whereas comparable qualitative results between the 2 detection systems were observed in this study (Table 1) , the absolute sensitivity of each method appeared less than optimal, with 71% and 76% of true-positives detected by the PBL and WB methods, respectively. High false-negative rates were likely due primarily to the fact that 26 (53%) of 49 true-positive samples were detected by the WB or PBL method alone but corroborated by prior or subsequent CMV testing (Table 1) . Other CMV antigenemia method comparisons have reported similar findings. For example, Visser et al 12 observed 8 (27%) of 30 positive samples detected by only 1 of 2 methods (4 per method). Similarly, St George and colleagues 13 noted that 33 (31.1%) of 106 positive results were generated by only 1 of the 2 methods under study (20 by one assay and 13 by the comparator). Both groups surmised that random sampling variation in specimens with very low antigenemia levels was the most probable explanation for discrepant results. In our study, we found that the 23 of 26 samples positive by only 1 of the 2 assays contained 5 or fewer pp65+ cells/10 6 WBCs. Furthermore, the 26 individually positive samples were evenly distributed between the 2 assays (12 vs 14), as they appear to have been in the aforementioned studies. Therefore, we too conclude that sampling variation in specimens with low antigenemia levels likely accounted for discrepant values and, hence, low calculated sensitivities in our study.
Still, we observed a much higher proportion of individually positive samples than did the prior studies-53% compared with 27% 12 and 31.1% 13 . Because the total number of leukocytes transferred to a slide and stained will ultimately affect the analytic sensitivity of the assay, 14, 15 we suspect that interrogation of very high numbers of WBCs by each of our methods resulted in high analytic sensitivities and, as a result, inclusion of many low-positive antigenemic samples. Assuming 100% WBC recovery, the median number of total WBCs assessed by each of our methods for positive samples would have been 700,000 per slide for the WB method and 350,000 per slide for the PBL method, somewhat higher than in other studies. 12, 13 One possible limitation of antigenemia testing in general, and of the described WB method in particular, is that insufficient numbers of WBCs may negatively impact sensitivity and negative predictive value. Furthermore, because all hematopoietic cell transplant recipients will be severely leukopenic for some duration, this drawback is a legitimate concern for monitoring patients within this population. Although there were no conclusive differences between methods at various leukocyte counts (Tables 2 and 3) , the overall pp65 positivity rate was significantly higher for samples with WBC counts more than 1,000/µL (1.0 × 10 9 /L; 48/324 [14.8%]) compared with samples having 1,000/µL (1.0 × 10 9 /L) or fewer (1/39 [35%]; P = .04; Fisher exact test). The difference remained significant even after combining the 38 additional leukopenic samples from the extended phase of the study (53/354 vs 2/47; P = .04).
In the absence of supplemental testing by a distinct method that relies less heavily on the WBC concentration, we were unable to determine whether or what proportion of negative results among these leukopenic samples may have been falsely negative by both antigenemia methods. As a safeguard against reporting false-negative results due solely to leukopenia, we required the presence of 100 or more counterstained cells per 200× field to consider a sample adequate. During the study, 6 samples were excluded from analysis owing to insufficient cells by one or the other method. All of these samples were obtained from patients with WBC levels of 700/µL (0.7 × 10 9 /L) or less. Taken together, these observations lend indirect support to the idea that polymerase chain reaction-based assays using cell-free matrices for CMV monitoring may be superior to immunologically based methods during periods of leukopenia. 9 Next we examined the correlation and the level of agreement between quantitative values of the 23 concordantly positive samples. By contrast, previous studies have relied solely on the former to conclude that no statistical difference in CMV antigenemia levels existed between the comparator assays in question. 13, 14, 16 As in these reports, we also calculated excellent correlation (r = 0.99) and observed no statistical differences by using the Wilcoxon signed rank test (P = .80). Yet, analysis of the log-transformed data (Figure 2 ) using methods described by Bland and Altman 11 suggests that replacement of our PBL assay by the WB method could impact clinical decision algorithms. To illustrate, consider a strategy for which preemptive antiviral therapy is initiated on detection of 20 pp65+ cells/10 6 WBCs using our standard PBL protocol. A sample with 3 pp65+ cells/10 6 WBCs by PBL not meeting intervention criteria would be expected (with 95% confidence) to contain between 0 and 30 pp65+ cells/10 6 WBCs if tested by the WB procedure, indicating that therapy would be instituted unnecessarily at least part of the time. On the other hand, a sample containing 50 pp65+ cells/10 6 WBCs by the PBL method and clearly meeting criteria for preemptive therapy would contain between 5 and 500 pp65+ cells/10 6 WBCs by the WB method, suggesting that therapy would occasionally be delayed in some patients. Therefore, without a prospective outcomes-based study comparing the actual clinical predictive value of the 2 antigenemia procedures, these results would seem to advise against substitution of the PBL procedure by the WB method.
